Hematology

Recent research highlights the significant underuse of disease-modifying therapies for sickle cell disease, despite their established benefits in reducing pain and preventing organ damage.

Multiple myeloma patients with two or more high-risk genetic abnormalities face significantly poorer outcomes, regardless of disease stage or treatment.

Bleeding risk from anticoagulants varies by gender and age in venous thromboembolism treatment, especially during the initial phase.

Donor age and cell dose significantly influence outcomes in haploidentical stem cell transplants, reveals new research.

New research finds no evidence linking sickle cell trait to acute pain crises or sudden death during exertion.

A Phase III trial shows adding daratumumab to VRd enhances treatment response in transplant-ineligible multiple myeloma patients.

Nonselective β-blockers may impair haematopoietic regeneration after transplantation, particularly with post-transplant chemotherapy.

Genetic analysis of 527 rare bleeding disorder cases reveals novel variants, according to research presented at the EAHAD 2024 Annual Congress.